NUCLEIC ACIDS RESEARCH, published by Oxford University Press, is a premier peer-reviewed journal in the field of genetics, holding a prestigious Q1 ranking in this domain as of 2023. Since its inception in 1974 and with a converged publication horizon extending to 2024, this journal has established itself as a vital resource for researchers and professionals interested in the molecular aspects of nucleic acids, encompassing DNA and RNA studies as well as their implications in biochemistry and molecular biology. With an impressive Scopus rank of #6 out of 347 in Genetics, this journal is positioned in the 98th percentile among its peers, highlighting its significant impact and relevance in the scientific community. As an open access journal since 2005, NUCLEIC ACIDS RESEARCH ensures wide dissemination of knowledge, promoting collaborative advancements in genetic research. For those looking to stay at the forefront of nucleic acid research, this journal remains an essential publication for accessing cutting-edge findings and innovative methodologies in the field.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

Molecular Cell, published by Cell Press, is a leading journal in the fields of cell biology and molecular biology. Established in 1997, this prestigious journal boasts a significant impact within the scientific community, evidenced by its impressive 2023 Scopus rankings, placing it in the top 2% of its field (Rank #10/410 in Molecular Biology, Rank #12/285 in Cell Biology). With a focus on cutting-edge research that bridges the gap between molecular genetics and cellular function, Molecular Cell serves as an essential platform for the dissemination of vital findings and innovative methodologies. Although it follows a traditional publishing model without Open Access options, its rigorous peer-review process and high standards ensure that articles published within these pages are of the utmost quality, making it an invaluable resource for researchers, professionals, and students alike seeking to stay at the forefront of scientific discovery. The journal's address is 50 Hampshire St, Floor 5, Cambridge, MA 02139, United States, reinforcing its commitment to fostering scientific excellence and collaboration.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Non-Coding RNA is a prestigious open-access journal published by MDPI, based in Switzerland, dedicated to the significant and rapidly evolving field of non-coding RNA research. Established in 2015, this journal has quickly become an essential resource for researchers and professionals, showcasing innovative studies and breakthroughs related to the functions and mechanisms of non-coding RNAs in various biological processes. With an impressive Q1 ranking in Biochemistry and strong rankings in Genetics and Molecular Biology, Non-Coding RNA consistently reflects the highest standards of academic publishing. The journal provides comprehensive access options, granting researchers worldwide the ability to disseminate and access high-quality research without subscription barriers. As the landscape of genomics and molecular discoveries continues to expand, the journal aims to foster interdisciplinary exchanges and collaborations, making it a vital platform for advancing knowledge and innovation in this critical area of biological science.

RSC Chemical Biology is a prestigious journal published by the Royal Society of Chemistry, providing a significant platform for researchers in the fields of biochemistry, genetics, and molecular biology. Launched in 2020, the journal aims to disseminate high-quality research that bridges the gap between chemistry and biology, promoting interdisciplinary studies and innovations that are essential for advancements in life sciences. With an emerging impact factor and ranking in the top quartile (Q1) for multiple categories such as Biochemistry and Molecular Biology, RSC Chemical Biology holds a prominent position in the academic landscape, evidenced by its Scopus rankings placing it in the top 20% and 30% of its respective fields. Although it does not operate under an open-access model, the journal's commitment to accessibility is reflected in its rigorous peer-review process and its role in shaping future scientific discourse. Research published in this journal is vital for contributing to our understanding of complex biological processes and fostering innovations that can lead to real-world applications.

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

RNA Biology is a premier journal published by Taylor & Francis Inc, focusing on the intricate and evolving field of RNA research. With an ISSN of 1547-6286 and E-ISSN of 1555-8584, this journal has established itself as an essential resource for professionals, researchers, and students engaged in both molecular and cell biology. Recognized in the 2023 quartile rankings, RNA Biology holds a distinguished Q1 category in Molecular Biology and a Q2 category in Cell Biology, indicative of its significant impact and reputation within the scientific community. The journal emphasizes the importance of RNA in various biological processes, highlighting both fundamental and applied aspects, which is crucial for advancing our understanding of gene expression and regulation. With a strong Scopus ranking, including Rank #105/410 in Molecular Biology and Rank #83/285 in Cell Biology, RNA Biology is not just a publication but a vital platform for sharing groundbreaking findings and insights into RNA research. With a convergence that spans from 2004 to 2024, the journal promises to continue its legacy of excellence in disseminating important discoveries in RNA science, contributing richly to ongoing scientific dialogue and innovation.

Molecular Therapy Methods & Clinical Development, published by CELL PRESS, is a premier Open Access journal dedicated to advancing the field of gene and cell therapy through innovative methodologies and clinical developments. Since its inception in 2014, the journal has garnered significant attention within the research community, achieving impressive Q1 quartile rankings in Genetics, Molecular Biology, and Molecular Medicine as of 2023. With a commendable Scopus ranking that positions it within the top echelons of its categories, this journal serves as an essential platform for researchers, professionals, and students alike, providing access to cutting-edge research that drives the future of therapeutic approaches. With its commitment to Open Access, readers worldwide can easily access high-quality and impactful content that fosters collaboration and knowledge-sharing in this rapidly evolving domain. The journal’s scope encompasses crucial advancements in therapeutic methodologies, ensuring that it remains at the forefront of scientific discourse and innovation.